Patient selection
DLBCL
The main inclusion criterion was biopsy‐confirmed CD20(+) DLBCL NOS, according to the WHO 2017 criteria. All patients were from 18 to 65 years old. According to Russian legislation, a majority is reached at the age of 18 and younger patients are treated according to pediatric protocols. The peak age was selected to better match previous RCTAll patients had stage IV and high‐intermediate/high IPI scores (IPI ≥2). Stage IV was assessed by Lugano classification.All patients had to be treated with chemotherapy of x6 R‐CHOP or x6 DA‐EPOCH‐R and achieved complete (CR) or partial (PR) response, classified by Lugano Response Criteria by the end of treatment. If PET‐CT was unavailable, the response was classified by CT and biopsy.A total of 516 patients with C83.3 treated from Jan 2010 to Dec 2019 at NMRC of oncology n.a. N.N.Petrov were analyzed to meet the inclusion criteria of this study. After that, exclusion criteria were applied.Firstly, age‐mismatched (Then, patients with SD/PD (In the end, we obtained 105 patients for further analyses (Figure Study design.The upfront group (Both “steady‐state” (filgrastim 10 μg/kg/day SC), and chemotherapy‐based protocols (DHAP ± R + filgrastim 5 μg/kg/day SC or cyclophosphamide 2 g/mInformed consent was obtained from the patients before data collection, following institutional guidelines, and the study was approved by the Committees for the Ethical Review of Research at NMRC of oncology n.a. N.N.Petrov.